These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry). Hanna NN, Gaglia MA, Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Am J Cardiol; 2010 Aug 15; 106(4):504-10. PubMed ID: 20691308 [Abstract] [Full Text] [Related]
15. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL, SPIRIT III Investigators. Circulation; 2009 Feb 10; 119(5):680-6. PubMed ID: 19171853 [Abstract] [Full Text] [Related]
16. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population. Laynez A, Sardi G, Hauville C, Barbash IM, Pakala R, Torguson R, Xue Z, Satler LF, Pichard AD, Waksman R. Catheter Cardiovasc Interv; 2013 Apr 10; 81(5):759-65. PubMed ID: 22488756 [Abstract] [Full Text] [Related]
17. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry. Lee JY, Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Park SW, Park SJ. J Am Coll Cardiol; 2009 Aug 25; 54(9):853-9. PubMed ID: 19695467 [Abstract] [Full Text] [Related]